ey0019.4-7 | Long-acting growth hormone (LAGH) | ESPEYB19
L Sa¨vendahl
, T Battelino
, MH Rasmussen
, M Brod
, P Saenger
, R Horikawa
J Clin Endocrinol Metab, 2022. 107(5): p. 1357-1367. PMID: 34964458Brief Summary: This multicenter, randomized, controlled, phase 2 study compared the effects of once-weekly long-acting growth hormone (GH) somapacitan versus daily GH administered to GH-deficient (GHD) children over a period of 156 weeks. Efficacy estimates were height velocity (HV; cm/y) at year 3 and changes from baseline to end for height SDS, HV SDS, IGF-I SDS, and insulin-li...